Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMI4O92)

Drug Name

LFA-102 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Prolactin receptor (PRLR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Endostatin	DM8NLDI	Solid tumour/cancer	2A00-2F9Z	Phase 2	[3]
Prolanta	DMLKF3H	Fallopian tube cancer	2C74	Phase 1	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT01610050) A Phase I Study of LFA102 in Japanese Patients. U.S. National Institutes of Health.
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1721).
3	Prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer. Cancer Res. 2003 Jul 1;63(13):3598-604.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)